Pliant Therapeutics, Inc. — Form 8-K Summary
Report date: February 27, 2024
Reporting period: Fourth quarter ended December 31, 2023
Business Context and Filing Purpose
Pliant Therapeutics, Inc. furnished this Form 8-K under Item 2.02 to announce the issuance of a press release reporting its financial results for the fourth quarter ended December 31, 2023. The filing identifies Pliant as a Delaware corporation headquartered in South San Francisco, California, with common stock trading on Nasdaq under the symbol PLRX.
Financial Results and Key Metrics
The filing text provided does not include the underlying press release or specific financial results. Accordingly, revenue, net income or loss, cash flow, operating expenses, margins, debt, cash and equivalents, liquidity, and other financial metrics are not stated clearly in the supplied content.
Material Changes Versus Prior Comparable Period
The supplied filing text does not provide comparative financial data or a clear description of changes from the fourth quarter of the prior year.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items are included in the supplied filing text. These matters may have been addressed in Exhibit 99.1, the referenced press release, but that exhibit’s contents are not provided.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the detailed fourth-quarter 2023 financial results.
- Verify cash, cash equivalents, investments, operating cash burn, and expected liquidity runway.
- Verify revenue, net loss, research and development expense, general and administrative expense, and per-share results.
- Review management’s forward-looking guidance, clinical-program updates, and stated risks or contingencies.
- Note that the Form 8-K states the information and furnished exhibits are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings.